article thumbnail

Post-stent chest pain, revisited

Heart Sisters

Heart patients with persistent or recurrent post-stent chest pain present “an unmet clinical need”, according to the European Journal of Cardiology.

article thumbnail

Dual-Antiplatelet Therapy After Drug-Eluting Stenting in ACS

JAMA Cardiology

This systematic review and network meta-analysis investigates the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention with drug-eluting stents.

Stent 99
article thumbnail

HonorHealth Research Institute First in Southwest to Implant New Stroke Prevention Stent

DAIC

This new system combines a truly innovative stent design,” said Dr. Ramaiah, a former director of the Arizona Heart Hospital. “We She already has three stents in her heart and so many stents and replacement arteries in both her legs that she’s lost count. The physician who performed the procedure, Venkatesh Ramaiah, M.D.,

Stents 111
article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].

Stent 105
article thumbnail

Early Win for Preemptive Stents on Vulnerable Coronary Plaque

Med Page Today

(MedPage Today) -- ATLANTA -- The concept of using stents to seal off non-flow-limiting vulnerable plaques, before they have a chance to rupture, worked out in the first major trial testing this provocative idea. Compared with standard medical.

Plaque 110
article thumbnail

Efficacy of IVUS-guided stent implantation in patients with complex CAD: a meta-analysis based on RCTs

Frontiers in Cardiovascular Medicine

0.85, P = 0.004), target vessel revascularization (TVR) (P = 0.01), target lesion revascularization (TLR) (P = 0.03) and stent thrombosis (ST) (P = 0.002) in the experimental group (IVUS-guidance) was lower than that in the control group (non-IVUS-guidance). The results showed that the incidence of MACE (RR: 0.63, 95% CI: 0.49–0.82,

Stent 52
article thumbnail

SMT Publishes Trial Results for Supraflex Cruz Stent

DAIC

Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).

Stent 52